Loading...
XNAS
EKSO
Market cap11mUSD
Dec 05, Last price  
4.29USD
1D
5.41%
1Q
6.19%
Jan 2017
-92.81%
IPO
-98.26%
Name

Ekso Bionics Holdings Inc

Chart & Performance

D1W1MN
XNAS:EKSO chart
P/E
P/S
0.63
EPS
Div Yield, %
Shrs. gr., 5y
33.28%
Rev. gr., 5y
5.19%
Revenues
18m
-1.94%
2,706,0003,302,0005,327,0008,661,00014,221,0007,353,00011,332,00013,917,0008,882,00011,246,00012,912,00018,279,00017,925,000
Net income
-11m
L-25.45%
-15,042,000-12,292-33,769,000-19,590,000-23,470,000-29,122,000-26,992,000-11,694,000-16,954,000-8,432,000-14,604,000-15,198,000-11,330,000
CFO
-10m
L-18.32%
-11,992-15,007,000-18,269,000-24,997,000-31,226,000-22,165,000-15,772,000-8,755,000-11,156,000-14,688,000-12,054,000-9,846,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
IPO date
Apr 10, 2013
Employees
72
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT